Market sentiment inevitably fluctuates when net profits from the 2025 annual newspaper disclosure in the comfort industry decline. However, an in-depth analysis of the basic aspects of the pharmaceutical company in the home reveals that the short-term performance constraints lie behind the firm's strategic input and solid layout for long-term development. From research and development strength to smart manufacturing, from biopharmaceutical breakthroughs to market innovation, the regenerative industry is quietly building core competitiveness for the future。
Research and development of the moat: eight years of hard power
In the area of chinese medicine innovation, there is no doubt about the leading position of the relic industry. For eight consecutive years, the company has been at the top of the top50 china drug research and development list, an achievement that is unique in industry. By the end of 2025, the kanko pharmaceutical industry had received 60 new chinese medicines and had over 700 patents for effective inventions, including two chinese patent gold awards. Behind these figures are the continued high level of corporate investment in r&d and the elaborate construction of innovative drug r&d systems。
In 2025, r & d conversion capacity in the cyanide industry was further demonstrated. The new chinese drug 1. 1, which treats the after-effects of pelvic inflammation, has been approved for listing; the innovative drug kys 2301, which treats specific skin disease, and the new chinese drug 1. 1, which treats diarrhea intestinal irritability, have subsequently received clinical approvals. It's even more important to note the way in which the medicine industry is organized around the global medical dilemma of alzheimer's disease. – the second phase of the trial for the mild and moderate alzheimer's disease in fluoride tablets has been completed and the second phase of the trial for the general capsules has been initiated。
Smart manufacturing: leading to the modernization of the chinese pharmaceutical industry
When traditional chinese medicine meets with modern technology, the cyanide industry chooses the front line of integration. The company has several national scientific platforms, such as the national priority laboratory for control of chinese pharmaceutical processes and smart manufacturing technologies and the national centre for joint local engineering research on chinese drug intelligent manufacturing technologies, and has been awarded the title "sexual smart plant" by the ministry of industry and communications. The production plants that have entered the cuisine industry have long lost sight of the old pots and have been replaced by a fully automatic chinese drug extraction line. Through a multifunctional extraction tank and digitization system, precision online control of the whole production process is being achieved. Particularly critical is the “total solid mass detection” based on the light technology — without the need for cumbersome chemical reagents, with only one beam passing through the sample to complete the composition determination at the millisecond level, which provides an efficient, non-destructive new quality control programme for chinese medicine. This change in the cuisine industry has not only boosted production capacity significantly, but has also contributed to quality management moving from the “post-exposure” of the past to the “cross-the-trace” of data, so that the safety and equality of medicines in every taste is guaranteed by a hard core。
Biopharmaceutical breakthrough: new growth poles under the one wing strategy
As the era has evolved, the cyanobactivism industry has long fallen short of the single track of chinese medicine, with chinese medicine as the main subject, chemicals and biopharmaceuticals as two wings and three drugs developing in tandem. In 2024, the company also acquired four clinical stages of biopharmaceutical pharmacies, including reorganisation of human neurogrowth factor injection fluids, droplet fluids and double/triple target integration proteins. In 2025, the development of these bioinnovators accelerated: the first type of innovation drug for treating overweight or obese, type 2 diabetes, zx2021, which has completed the second stage of the test, entered the group and has already had a weight reduction effect in a blind state; and the zx2010 dose for accompaniment has also entered the second stage of the clinical phase。
Market innovation: changes in the channels of input into new retailing
In the face of changes in the market environment, the relics industry does not adhere to traditional channels. In august 2025, the company announced a special distribution of the new retail field of medicine, a strategic layout that focuses on core items such as vinyl oscillation fluids, cosmopolitan pain ointment and almond cough particles. These products are not only the legacy of chinese medicine, but also the integration of modern science and technology into the organic combination of traditional essences and modern technology. They will lock into the shivering, the red book and the private domain matrix, which is designed to create a closed market model for "precision extension-platform orientation-door compliance", and the company's rich product matrix, which provides ample preparation for change in this channel。
Long-term values: short-term commitment to business transformation
It is worth noting that, despite the decline in the performance of the pharmaceutical industry throughout 2025, the strong rebound in the fourth quarter is of concern: 950 million yuan, an increase of 20. 15 per cent over the same period, and a net profit of 104 million yuan, a rise of 27. 6 per cent over the same period. I can say
In 2025, the performance of the ecstasy industry was reversed, not by the relaxation of the basic disks, but by the `conversion deceleration' of the transition period. When most pharmacists are still in the stock market, the relics have quietly completed the conversion of old and new kinetic energy through intensive research and development inputs, intelligent manufacturing upgrades and a strategic “triple drug coupling”。
As the fourth quarter of 2025 saw a turning point in performance and biopharmaceutical pharmacies matured, the market's concerns about the cyanide industry might be overcome by solid fundamentals over time. The path to transition is not flat, but it is clear and steady. What we see is the determination and background of an old chinese pharmaceutical company to try to break the ceiling and reshape the logic of valuation. We also wait for this long-deep “innovation fire”, which could burn the way in the 2026 performance survey。
